---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-128598"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T07:48:26.437989+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS initiates arbitration against 3D Medicines over $13M milestone payments and GPS development in China

## Summary
- Dispute over $13M development milestone payments due under 2020 license agreement for GPS in China region.
- 3D Medicines enrolled patients in Taiwan but failed to begin mainland China enrollment as expected in H2 2023.
- SELLAS claims 3D Medicines failed to use commercially reasonable best efforts; arbitration filed at HKIAC under NY law.
- Company cannot predict arbitration outcome or timing of any milestone payments or damages.

## SEC filing metadata
- accession: 0001104659-23-128598
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465923128598/0001104659-23-128598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465923128598/tm2333390d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-128598
- JSON: https://secwatch.observer/filing/0001104659-23-128598.json
- Plain text: https://secwatch.observer/filing/0001104659-23-128598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.